Kymera Therapeutics Inc (KYMR, Financial) is set to release its Q3 2024 earnings on Oct 31, 2024. The consensus estimate for Q3 2024 revenue is $10.36 million, and the earnings are expected to come in at -$0.84 per share. The full year 2024's revenue is expected to be $56.62 million and the earnings are expected to be -$2.91 per share. More detailed estimate data can be found on the Forecast page.
Kymera Therapeutics Inc (KYMR, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Kymera Therapeutics Inc (KYMR) for the full year 2024 have increased from $53.32 million to $56.62 million. For 2025, the estimates have risen slightly from $67.44 million to $67.85 million. Earnings estimates for the full year 2024 have improved from -$2.98 per share to -$2.91 per share. However, for 2025, the earnings estimates have declined from -$3.28 per share to -$3.44 per share.
Kymera Therapeutics Inc (KYMR, Financial) Reported History
In the previous quarter of 2024-06-30, Kymera Therapeutics Inc's (KYMR) actual revenue was $25.65 million, which beat analysts' revenue expectations of $12.554 million by 104.32%. Kymera Therapeutics Inc's (KYMR) actual earnings were -$0.58 per share, which beat analysts' earnings expectations of -$0.723 per share by 19.78%. After releasing the results, Kymera Therapeutics Inc (KYMR) was down by -2.68% in one day.
Kymera Therapeutics Inc (KYMR, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 15 analysts, the average target price for Kymera Therapeutics Inc (KYMR) is $56.27 with a high estimate of $106 and a low estimate of $36. The average target implies an upside of 16.04% from the current price of $48.49.
Based on GuruFocus estimates, the estimated GF Value for Kymera Therapeutics Inc (KYMR, Financial) in one year is $25.21, suggesting a downside of -48.01% from the current price of $48.49.
Based on the consensus recommendation from 17 brokerage firms, Kymera Therapeutics Inc's (KYMR, Financial) average brokerage recommendation is currently 1.9, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
